Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.
Reduced circadian rhythmicity is associated with an increased risk for incident Parkinson disease.
Researchers sought to determine the relationship between neuroimaging markers and other clinical characteristics with mild parkinsonian signs in older adults.
Precision medicine offers a promising therapeutic strategy for patients with Parkinson disease, allowing for tailored treatments which reflect the unique pathophysiology in each patient.
Treatment with deutetrabenazine was found to be beneficial for both younger (<55 years) and older (≥55 years) patients with tardive dyskinesia, according to findings from a recently published post hoc analysis.
Severe neuropsychiatric dysfunction, including psychosis and dementia, is associated with more advanced Parkinson disease.
A study found a causally protective effect of tobacco smoking on the risk of Parkinson disease.
More research is needed to determine the safety and efficacy of cannabis use for the treatment of Parkinson disease symptoms.
Pimavanserin, either alone or in conjunction with a selective serotonin reuptake inhibitor or serotonin–norepinephrine reuptake inhibitor, may improve comorbid depression symptoms in patients with Parkinson disease.
Compared to the general population, patients with Parkinson disease report a higher prevalence of ophthalmologic symptoms.